Potential Clinical Benefits of Quercetin in the Early Stage of COVID-19 : Results of a Second, Pilot, Randomized, Controlled and Open-Label Clinical Trial
© 2021 Di Pierro et al..
BACKGROUND: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of the ongoing global pandemic known as COVID-19. Based on the potential antiviral role of quercetin, and on its described anti-blood clotting, anti-inflammatory and antioxidant properties, we hypothesize that subjects with mild COVID-19 treated with Quercetin Phytosome® (QP), a novel bioavailable form of quercetin, may have a shorter time to virus clearance, a milder symptomatology, and higher probabilities of a benign earlier resolution of the disease.
METHODS: In our 2-week, randomized, open-label, and controlled clinical study, we have enrolled 42 COVID-19 outpatients. Twenty-one have been treated with the standard of care (SC), and 21 with QP as add-on supplementation to the SC. Our main aims were to check virus clearance and symptoms.
RESULTS: The interim results reveal that after 1 week of treatment, 16 patients of the QP group were tested negative for SARS-CoV-2 and 12 patients had all their symptoms diminished; in the SC group, 2 patients were tested SARS-CoV-2 negative and 4 patients had their symptoms partially improved. By 2 weeks, the remaining 5 patients of the QP group tested negative for SARS-CoV-2, whereas in the SC group out of 19 remaining patients, 17 tested negatives by week 2, one tested negative by week 3 and one patient, still positive, expired by day 20. Concerning blood parameters, the add on therapy with QP, reduced LDH (-35.5%), Ferritin (-40%), CRP (-54.8%) and D-dimer (-11.9%).
CONCLUSION: QP statistically shortens the timing of molecular test conversion from positive to negative, reducing at the same time symptoms severity and negative predictors of COVID-19.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
International journal of general medicine - 14(2021) vom: 01., Seite 2807-2816 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Di Pierro, Francesco [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
CRP |
|---|
| Anmerkungen: |
Date Revised 24.04.2022 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.2147/IJGM.S318949 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM327410116 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM327410116 | ||
| 003 | DE-627 | ||
| 005 | 20231225200726.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2147/IJGM.S318949 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1091.xml |
| 035 | |a (DE-627)NLM327410116 | ||
| 035 | |a (NLM)34194240 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Di Pierro, Francesco |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Potential Clinical Benefits of Quercetin in the Early Stage of COVID-19 |b Results of a Second, Pilot, Randomized, Controlled and Open-Label Clinical Trial |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 24.04.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2021 Di Pierro et al. | ||
| 520 | |a BACKGROUND: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of the ongoing global pandemic known as COVID-19. Based on the potential antiviral role of quercetin, and on its described anti-blood clotting, anti-inflammatory and antioxidant properties, we hypothesize that subjects with mild COVID-19 treated with Quercetin Phytosome® (QP), a novel bioavailable form of quercetin, may have a shorter time to virus clearance, a milder symptomatology, and higher probabilities of a benign earlier resolution of the disease | ||
| 520 | |a METHODS: In our 2-week, randomized, open-label, and controlled clinical study, we have enrolled 42 COVID-19 outpatients. Twenty-one have been treated with the standard of care (SC), and 21 with QP as add-on supplementation to the SC. Our main aims were to check virus clearance and symptoms | ||
| 520 | |a RESULTS: The interim results reveal that after 1 week of treatment, 16 patients of the QP group were tested negative for SARS-CoV-2 and 12 patients had all their symptoms diminished; in the SC group, 2 patients were tested SARS-CoV-2 negative and 4 patients had their symptoms partially improved. By 2 weeks, the remaining 5 patients of the QP group tested negative for SARS-CoV-2, whereas in the SC group out of 19 remaining patients, 17 tested negatives by week 2, one tested negative by week 3 and one patient, still positive, expired by day 20. Concerning blood parameters, the add on therapy with QP, reduced LDH (-35.5%), Ferritin (-40%), CRP (-54.8%) and D-dimer (-11.9%) | ||
| 520 | |a CONCLUSION: QP statistically shortens the timing of molecular test conversion from positive to negative, reducing at the same time symptoms severity and negative predictors of COVID-19 | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Clinical Trial | |
| 650 | 4 | |a CRP | |
| 650 | 4 | |a D-dimer | |
| 650 | 4 | |a LDH | |
| 650 | 4 | |a RT-PCR | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a coronavirus | |
| 650 | 4 | |a ferritin | |
| 650 | 4 | |a phytosome® | |
| 700 | 1 | |a Iqtadar, Somia |e verfasserin |4 aut | |
| 700 | 1 | |a Khan, Amjad |e verfasserin |4 aut | |
| 700 | 1 | |a Ullah Mumtaz, Sami |e verfasserin |4 aut | |
| 700 | 1 | |a Masud Chaudhry, Mohsin |e verfasserin |4 aut | |
| 700 | 1 | |a Bertuccioli, Alexander |e verfasserin |4 aut | |
| 700 | 1 | |a Derosa, Giuseppe |e verfasserin |4 aut | |
| 700 | 1 | |a Maffioli, Pamela |e verfasserin |4 aut | |
| 700 | 1 | |a Togni, Stefano |e verfasserin |4 aut | |
| 700 | 1 | |a Riva, Antonella |e verfasserin |4 aut | |
| 700 | 1 | |a Allegrini, Pietro |e verfasserin |4 aut | |
| 700 | 1 | |a Khan, Saeed |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of general medicine |d 2008 |g 14(2021) vom: 01., Seite 2807-2816 |w (DE-627)NLM197053971 |x 1178-7074 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2021 |g day:01 |g pages:2807-2816 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2147/IJGM.S318949 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2021 |b 01 |h 2807-2816 | ||